aTyr Pharma (ATYR) announced that it has advanced its next investigational new drug, IND, candidate, ATYR0101, which has been selected to be showcased in an oral presentation at the American Thoracic Society, ATS, 2025 Respiratory Innovation Summit, which is scheduled to take place May 16 – 17, 2025, in San Francisco, CA. The presentation will feature preclinical data generated to date for ATYR0101, a fusion protein derived from a proprietary extracellular domain of aspartyl-tRNA synthetase, DARS, that binds to latent transforming growth factor beta binding protein 1 to induce cell death of myofibroblasts, which are key cells responsible for driving the progression of fibrosis.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- Positive Outlook for aTyr Pharma: Buy Rating Reaffirmed Amid Promising EFZO-FIT Trial Prospects
- Promising Outlook for aTyr Pharma: Phase 3 Study Progress and Potential Stock Upside
- Promising Clinical Advancements and Financial Stability Drive Buy Rating for aTyr Pharma
- Promising Outlook for aTyr Pharma’s Efzofitimod and Strong Financial Position Reinforce Buy Rating
- aTyr Pharma reports Q1 EPS (17c), consensus (19c)